We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
- Authors
Palandri, Francesca; Elli, Elena M.; Auteri, Giuseppe; Bonifacio, Massimiliano; Benevolo, Giulia; Heidel, Florian H.; Paglia, Simona; Trawinska, Malgorzata M.; Bosi, Costanza; Rossi, Elena; Tiribelli, Mario; Tieghi, Alessia; Iurlo, Alessandra; Polverelli, Nicola; Caocci, Giovanni; Binotto, Gianni; Cavazzini, Francesco; Beggiato, Eloise; Cilloni, Daniela; Tatarelli, Caterina
- Abstract
Discussion This study provides epidemiological data on Covid19 infection in MPN patients treated with ruxolitinib, showing that 14.2% of such patients acquired the infection, with an incidence rate of 10.5 × 100 patients-years. Previous studies on Covid19 in MPN patients have included patients regardless of treatment type, with few patients treated with ruxolitinib at the time of the pandemic. Two venous thromboses occurred in Covid19 patients (all hospitalized) (IR 6.7 per 100 patient-years) and 10 thromboses occurred in non-Covid19 patients (IR 1.7 per 100 patient-years, I p i = 0.05).
- Subjects
MYELOFIBROSIS; OVERALL survival; COVID-19; RUXOLITINIB
- Publication
Blood Cancer Journal, 2023, Vol 13, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-023-00834-6